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12 months). RESULTS: Patients mean  SD age was
55  15 years and 77% were female. Mean  SD MAF
score was 23.3  12.3 with a normal range of 1(no fa-
tigue)–50(fatigue). Mean FACIT-F score was 33.2  9.3
with a normal range of 52 (no fatigue)–0 (fatigue). The
aggregate scores for each instrument were highly corre-
lated with a Pearson’s coefficient of 0.81 (p  0.001).
CONCLUSION: Based on this analysis, it appears that
the FACIT-F has validity for use in the early RA popula-
tion. However, as follow-up assessments are completed, a
more detailed analysis may reveal additional psychomet-
ric properties of the instrument in the early RA popula-
tion and with disease progression.
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OBJECTIVES: This review identifies instruments for
measuring functional status among workers with mild-
to-moderate disorders of the upper extremity. Functional
status measures correlate pain and discomfort to perfor-
mance, with direct, practical relevance to employers and
workers. While many functional status measures exist for
patients with severe or degenerative illness, few measures
were designed for relatively healthy active workers. In
fact, the impact of mild-to-moderate disorders on the
workforce is largely unknown. The recently released
OSHA Ergonomics Program Standard has given this issue
a new sense of urgency. The intent is to give investigators
a tool for choosing appropriate functional status mea-
sures in a specific research or clinical context. METH-
ODS: To identify self-reported functional status instru-
ments for upper extremity disorders among workers, a
Medline literature search was conducted for English-lan-
guage publications between the years 1966 and 2000.
Keywords included: carpal tunnel syndrome, functional
status, health surveys, musculoskeletal, occupational
health, outcome measures, questionnaire, neck, upper ex-
tremity, and worker. In selecting functional status instru-
ments for review, three criteria were used: 1) Relevance
to neck and upper extremity conditions (indicated by
question content); 2) Assessment among workers; and 3)
Relevance to mild-to-moderate disorders (indicated by
level of severity). Parameters of interest were validity,
reliability, and responsiveness to change. RESULTS:
Among 13 functional status instruments reviewed, six
measures were tested among workers, including three
measures relevant for mild-to-moderate disorders: the
Nordic Musculoskeletal Questionnaire, Upper Extremity
Questionnaire, and Neck and Upper Limb Instrument.
CONCLUSIONS: The identification of three functional
status measures should encourage their use in studies, to
improve communication among investigators. Further re-
search is needed to address neglected aspects of measure-
ment—specifically, for mild-to-moderate upper extremity
disorders among workers—and to standardize valid and
reliable instruments.
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OBJECTIVE: The aim of this study was to determine the
cost-effectiveness of Acetylcysteïne and DMSO in the
treatment of patients with reflex sympathic dystrophy
(RSD). METHODS: The study was a prospective, dou-
ble-dummy, double blind, controlled trial. Patients were
followed for one year. The primary outcome measure
was the Impairment-level Sum Score (ISS). Cost data
were prospectively collected using cost-diaries. Utilities
were determined using the EuroQol. Both cost-effective-
ness and cost-utility analyses were performed. Differ-
ences in mean direct, indirect and total costs between
groups were estimated with corresponding 95% Confi-
dence Intervals (CI). Also cost-effectiveness and cost-util-
ity ratios with corresponding 95% CI were calculated us-
ing bootstrapping techniques. RESULTS: There was a
statistically significant difference in effect (ISS). DMSO
generated more reduction than Acetylcysteïne (diff: 1.82
CI:4.90;1.27). This significant difference appeared
also in the subgroup of patients with warm RSD. The to-
tal costs were statistically significant lower in the DMSO
compared to the Acetylcysteïne group (diff: 2866 CI:
666;5179). This significant difference was also found in
the subgroup of patients with warm RSD. The cost-effec-
tiveness and cost-utility ratios showed that DMSO is
dominant over Acetylcysteïne. CONCLUSION: In gen-
eral, DMSO is the preferred method of treatment for pa-
tients with RSD. There are some indications that Acetyl-
cisteïne may be more cost-effective for cold RSD, but this
was found in a small subgroup only and should be con-
firmed in a larger trial.
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OBJECTIVES: This paper presents the results of an eco-
nomic evaluation in conjunction with a randomized con-
trolled trial to evaluate the cost-effectiveness of manual
therapy, physical therapy and GP care for patients with
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neck pain. METHODS: Patients were recruited by 42
general practitioners if they had been suffering from neck
pain for at least two weeks. The 183 patients were ran-
domly allocated to manual therapy (spinal mobilization,
n  60), physical therapy (exercise therapy and massage,
59), or GP care (counseling, education and medication,
n  64). Clinical outcomes included perceived recovery,
pain intensity, functional disability and quality of life
(EuroQol). Direct and indirect costs were measured by
means of cost diaries completed by patients during the in-
tervention period and the 52-week follow up. Differences
in mean costs between groups were evaluated by apply-
ing non-parametric bootstrapping techniques. RESULTS:
The total costs of the manual therapy (Euro 447) were
approximately one-third of the costs of the physical ther-
apy (Euro 1,297) and GP care (Euro 1,379). These differ-
ences were found to be statistically significant when
bootstrapping was applied. The cost-effectiveness ratios
and the cost-utility ratios showed that manual therapy
was dominant (less costly and more effective), compared
to physical therapy and GP care. The recovery rates
based on perceived recovery after 12 months were 72%
for manual therapy, 63% for physical therapy and 56%
for GP care. With regard to pain intensity and functional
disability, manual therapy was also found to be domi-
nant over time, compared to physical therapy and GP
care, for these clinical outcomes, although the differences
were small. CONCLUSIONS: This study showed that
manual therapy (spinal mobilization) is more effective
and less costly than physical therapy and GP care.
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Upon admission to a skilled nursing home facility, infor-
mation is recorded on a Minimum Data Set (MDS), a
400 item instrument used as the basis of 1) reimburse-
ment for Medicare eligible nursing home stays and 2)
care planning, survey and certification for all nursing
home stays. OBJECTIVE: To predict and evaluate vari-
ables related to hip fractures in the nursing home setting.
METHODS: Electronic MDS data was available from
200 homes for variable evaluation times. The first avail-
able Assessment Reference Date (A3A), was the baseline
for a regression of time to first fracture. Excluded were 1)
patients with a fracture having an A3A date within the
first 10 days of baseline visit, and 2) patients with 60
days of follow-up, from first to last A3A visit. Analysis
included a Kaplan-Meier curve summarizing time to frac-
ture, and a Cox Proportional Hazards regression model.
RESULTS: The initial data set included 23,045 patients.
11,465 met the inclusion criteria, and 336 of these had
fractures. Most important variables, based on the coeffi-
cient size, associated with increasing risk, were unsteady
gait, deterioration in ADL function, a hospital stay in the
last 90 days, use of full bed rails, and Alzheimer’s disease.
The risk was also higher among females and whites. The
need for full physical help while standing had a lower
risk when compared to need for less support, but this is
likely due to a lowered potential for falling, and increased
vigilance an the part of staff. “Deteriorated” ADL func-
tion had almost twice the risk when compared to “im-
proved” ADL. CONCLUSION: Unsteady gait, deteriora-
tion in ADL, use of bed rails, presence of Alzheimer’s
disease, and hospital admissions were associated with an
increased risk of hip fracture. A larger sample of fractures
would be more likely to be successful in studying addi-
tional relationships.
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BACKGROUND: Previous studies have demonstrated
that high levels of glucocorticoid (GC) exposure are asso-
ciated with increased fracture risk. However, none has
reported potential cost impacts. OBJECTIVE: To esti-
mate the marginal costs from vertebral fractures among
GC patients. METHODS: Subjects 18–64 years old with
different GC exposure levels, with and without fractures,
were selected (n  50,191). GC exposure was catego-
rized into three levels: high (3 claims of continuous use
or 9.5 prednisone-equivalent mg/day), low (other GC
use), and no GC use. Fractures, comorbid conditions,
and costs were determined 15 months before and up to
3.5 years after index date. Regression models were used
to estimate the marginal effects of vertebral fractures on
pharmacy costs, medical costs and total costs. The mod-
els controlled for age, gender, pre-index date costs, GC
exposure/fracture combinations, and pre-index and new
post-index date comorbid conditions. RESULTS: Verte-
bral fractures led to significant per-member per-month
(PMPM) cost increases in each GC exposure group. Fur-
thermore, the additional increase in marginal cost from
vertebral fracture on total PMPM costs among high GC
patients versus low GC patients was 83% ($170; p 
0.001). Differential increases in pharmacy and medical
PMPM costs between high and low GC patients were
151% ($56; p  0.01) and 68% ($115; p  0.014), re-
spectively. CONCLUSIONS: Vertebral fractures were as-
sociated with increased PMPM costs, holding constant
patients’ underlying conditions. High GC patients had
greater PMPM increases from vertebral fractures com-
